Adverse events184

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 184

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	COVID-19	Infections and infestations	Double Blind Benralizumab	22	144	23
other	COVID-19	Infections and infestations	Double Blind Placebo	16	143	16
other	COVID-19	Infections and infestations	Double Blind Benralizumab First, Then Open Label Benralizumab	9	122	9
other	COVID-19	Infections and infestations	Double Blind Placebo First, Then Open Label Benralizumab	7	125	7
other	Influenza	Infections and infestations	Double Blind Benralizumab	1	144	1
other	Influenza	Infections and infestations	Double Blind Placebo	3	143	3
other	Influenza	Infections and infestations	Double Blind Benralizumab First, Then Open Label Benralizumab	4	122	4
other	Influenza	Infections and infestations	Double Blind Placebo First, Then Open Label Benralizumab	1	125	1
other	Nasopharyngitis	Infections and infestations	Double Blind Benralizumab	11	144	12
other	Nasopharyngitis	Infections and infestations	Double Blind Placebo	9	143	10
other	Nasopharyngitis	Infections and infestations	Double Blind Benralizumab First, Then Open Label Benralizumab	9	122	10
other	Nasopharyngitis	Infections and infestations	Double Blind Placebo First, Then Open Label Benralizumab	8	125	9
other	Pneumonia	Infections and infestations	Double Blind Benralizumab	3	144	3
other	Pneumonia	Infections and infestations	Double Blind Placebo	1	143	1
other	Pneumonia	Infections and infestations	Double Blind Benralizumab First, Then Open Label Benralizumab	1	122	1
other	Pneumonia	Infections and infestations	Double Blind Placebo First, Then Open Label Benralizumab	4	125	4
other	Upper respiratory tract infection	Infections and infestations	Double Blind Benralizumab	13	144	16
other	Upper respiratory tract infection	Infections and infestations	Double Blind Placebo	14	143	18
other	Upper respiratory tract infection	Infections and infestations	Double Blind Benralizumab First, Then Open Label Benralizumab	9	122	10
other	Upper respiratory tract infection	Infections and infestations	Double Blind Placebo First, Then Open Label Benralizumab	4	125	5

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04157335/events

API reference For AI assistants

Adverse events184

Sources 3

Read this list from software.